1. Signaling Pathways
  2. Immunology/Inflammation
  3. Toll-like Receptor (TLR)
  4. TLR7 Isoform
  5. TLR7 Agonist

TLR7 Agonist

TLR7 Agonists (37):

Cat. No. Product Name Effect Purity
  • HY-13740
    Agonist 99.96%
    Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
  • HY-109104
    Agonist 98.98%
    Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity.
  • HY-B0180
    Agonist 99.96%
    Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist.
  • HY-103698
    TLR7/8 agonist 1
    TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline.
  • HY-13740G
    Resiquimod (GMP)
    Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines.
  • HY-153072
    TLR7 agonist 7
    TLR7 agonist 7 (compound IIb-26) is an TLR7 agonist with an EC50 value of ~4 nM.
  • HY-B0180A
    Imiquimod hydrochloride
    Agonist 99.80%
    Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist.
  • HY-111786
    Agonist ≥98.0%
    LHC-165 is a TLR7 agonist.
  • HY-110120
    Agonist 98.33%
    DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist, with EC50s of 7.2 nM and 4.6 nM for human and mice TLR7, respectively.
  • HY-103697A
    Gardiquimod diTFA
    Agonist ≥99.0%
    Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist.
  • HY-118250
    Agonist 99.84%
    GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties.
  • HY-130797
    TLR7/8 agonist 3
    Agonist 99.02%
    TLR7/8 agonist 3 is a potent TLR7 and TLR8 agonist, extracted from patent WO2016057618 (compound of formula (II)).
  • HY-115400
    Agonist 99.59%
    1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects.
  • HY-111269
    Agonist 98.08%
    AZD8848 is a selective toll-like receptor 7 (TLR7) antedrug agonist which is developed for the research of asthma and allergic rhinitis.
  • HY-108472
    Agonist 99.64%
    Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities.
  • HY-128799
    Agonist 99.89%
    CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages.
  • HY-145960
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4
    Agonist 99.39%
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate.
  • HY-111358
    TLR7 agonist 1
    Agonist 98.95%
    TLR7 agonist 1 is a potent, selective and oral TLR7 agonist with an IC50 of 90 nM.
  • HY-139017
    TLR7/8 agonist 4
    Agonist 99.04%
    TLR7/8 agonist 4 (compound 41) is a potent TLR7/8 agonist.
  • HY-145961
    TLR7 agonist 4
    Agonist 98.87%
    TLR7 agonist 4 (Compound 1.2) is a TLR7 agonist with an EC50 of 4.3 nM.